Trials / Recruiting
RecruitingNCT05247255
Quadratus Lumborum Block for Total Hip Arthroplasty
Quadratus Lumborum (QL) Nerve Block for Patients Undergoing Primary Total Hip Arthroplasty (THA)
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- University of California, Los Angeles · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The quadratus lumborum (QL) block is a fascial plane block that has been described to provide analgesia from T7-L3 dermatomes. The investigators aim to evaluate the efficacy of QL blocks in patients undergoing primary total hip arthroplasty (THA).
Detailed description
Investigators will enroll subjects planned for primary THA and allocate them into receiving a QL block with either saline or ropivacaine. Primary outcome will be pain scores over the first 48 hours after surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Active Comparator | QL block with 0.25% ropivacaine |
| DRUG | Placebo Comparator | QL block with saline |
Timeline
- Start date
- 2022-03-29
- Primary completion
- 2026-12-01
- Completion
- 2027-01-01
- First posted
- 2022-02-18
- Last updated
- 2025-12-29
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05247255. Inclusion in this directory is not an endorsement.